文章写好了,就剩投稿了,
这时你发现,怎么选SCI期刊?
如何避开那些
年发文量不高,
投稿周期又比较长的SCI
今天,给大家推荐一个SCI投稿必备公众号
“
51选刊
”!
扫描二维码即可关注“
51选刊
” (ID:
woyaoxuankan
)!
近两个月来,“
51选刊
”已发表的比较受欢迎的
公众
号文章:我们从各个角度为大家选择年发文量相对较多、影响因子一般3~5分的期刊,同时考虑大家的喜爱,选择接受时间短的期刊
进行
推荐。
4、
又一本国产的英文期刊被SCI收录,预计第1个影响因子超5分,或有实力冲击6分
5、
SCI发表之绿色快速通道:这本接近5分的SCI,最快可一周内接受
6、
这本英文期刊,周五刚被SCIE收录,明年第一个影响因子有望冲击3分
2
019年6月科睿唯安发布的期刊引证报告中,SAGE期刊呈现了良好的增长趋势。
今天,我们来看看这本SCI期刊:
Therapeutic Advances in Neurological Disorders
。
Therapeutic Advances in Neurological Disorders
是经过同行评审的开放获取期刊,
出版神经病学相关领域的前沿探索和创新研究
。
该刊最新影响因子(JCR2018)为
3.580
。
Therapeutic Advances in Neurological Disorders (TAND)
is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies across all areas of neurology.
Therapeutic Advances in Neurological Disorders
delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of neurological conditions. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in neurology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of neurology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include
laboratory, animal or human/clinical studies – all phases
. Letters to the Editor and
Case Reports will also be considered
.
Authors will enjoy:
-
Authors will enjoy:
-
-
Listed in PubMed, SCIE, Scopus and DOAJ
-
International expert Editorial Board and panel of Associate Editors
-
Rigorous and fast peer review
-
Average time from submission to first decision is 36 days
-
-
期刊主页:
-
https://journals.sagepub.com/home/tan
长按扫描上方二维码
访问
TAN
期刊首页,了解更多详情
近三年来,
Therapeutic Advances in Neurological Disorders